For 2024, Bavarian Nordic expected revenue of DKK 5,000 million - DKK 5,300 million. The expected revenue is comprised of DKK 2,700 million ? DKK 3,000 million from Public Preparedness vaccines, of which DKK 1,600 million have already been secured by contracts, approximately DKK 2,100 million from Travel Health vaccines and approximately DKK 200 million from contract work.

Travel Health anticipates a 12% growth, driven by a mix of continued market growth and market share gains.